Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term
management to optimise patient outcomes. The Pituitary Society convened a consensus …

Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …

Context Cabergoline is first-line treatment for most patients with lactotrope pituitary tumors
and hyperprolactinemia. Its use at high dosages in Parkinson disease (PD) has largely been …

Cabergoline is a dopamine agonist that has been used as the first-line treatment option for
prolactin-secreting pituitary adenomas for several decades. It not only suppresses hormone …

First-line treatment of prolactinoma is usually medical, based on dopamine agonists
receptors, mainly cabergoline. The classical side-effects of cabergoline (low blood pressure …

Background Controversy exists as to whether low-dose cabergoline is associated with
clinically significant valvulopathy. Few studies examine hard cardiac endpoint data, most …

This is a joint position statement of the British Society of Echocardiography, the British Heart
Valve Society and the Society for Endocrinology on the role of echocardiography in …

Hyperprolactinaemia can be physiological, pathological or drug induced. Elevated serum
prolactin concentration can cause secondary hypogonadism via inhibition of hypothalamic …

Glucokinase maturity-onset diabetes of the young (GCK-MODY) represents a distinct
subgroup of MODY that does not require hyperglycemia-lowering treatment and has very …

Dopamine agonists (DAs) represent a cornerstone in the management of patients with
hyperprolactinemia and have an important role in the treatment of neurologic disorders …